Sectors
TCRX
TScan Therapeutics, Inc.
0.76
1 x 0.77
18 x 0.77
bid
ask
-
0.00
0.44%
09:40 AM
timesize
| Ytd | -23.64% | |
| 1y | -52.57% |
0.76
day range
0.80
0.72
52 week range
2.57
| Open | 0.77 | Prev Close | 0.77 | Low | 0.76 | High | 0.80 | Mkt Cap | 46.64M |
| Vol | 9.83K | Avg Vol | 653.90K | EPS | -0.96 | P/E | -0.80 | Forward P/E | -2.33 |
| Beta | 1.06 | Short Ratio | 9.02 | Inst. Own | 86.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 0.92 | 200-d Avg | 1.08 | 1yr Est | 12.14 |
| Income Statement | |||
| Total Revenue | 982.00K | ||
| Revenues (USD) | 982.00K | ||
| Gross Profit | 982.00K | ||
| Operating Expenses | 30.12M | ||
| Research and Development Expense | 21.90M | ||
| Selling, General and Administrative Expense | 8.22M | ||
| Operating Income | -29.14M | ||
| Interest Expense | 689.00K | ||
| Net Income | -28.67M | ||
| Net Income Common Stock | -28.67M | ||
| Net Income Common Stock (USD) | -28.67M | ||
| Consolidated Income | -28.67M | ||
| Earnings per Basic Share | -0.22 | ||
| Earnings per Basic Share (USD) | -0.22 | ||
| Earnings per Diluted Share | -0.22 | ||
| Earning Before Interest & Taxes (EBIT) | -27.98M | ||
| Earning Before Interest & Taxes (USD) | -27.98M | ||
| Weighted Average Shares | 129.91M | ||
| Weighted Average Shares Diluted | 129.91M | ||
| Balance Sheet | |||
| Cash and Equivalents | 133.09M | ||
| Cash and Equivalents (USD) | 133.09M | ||
| Investments | 68.00K | ||
| Investments Non-Current | 68.00K | ||
| Current Assets | 132.77M | ||
| Property, Plant & Equipment Net | 64.13M | ||
| Total Assets | 201.99M | ||
| Debt Current | 7.44M | ||
| Total Debt | 92.54M | ||
| Current Liabilities | 19.97M | ||
| Debt Non-Current | 85.10M | ||
| Total Liabilities | 105.07M | ||
| Accumulated Retained Earnings (Deficit) | -533.53M | ||
| Shareholders Equity | 96.92M | ||
| Shareholders Equity (USD) | 96.92M | ||
| Assets Non-Current | 69.22M | ||
| Total Debt (USD) | 92.54M | ||
| Deferred Revenue | 1.64M | ||
| Liabilities Non-Current | 85.10M | ||
| Trade and Non-Trade Payables | 2.30M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 693.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -24.35M | ||
| Capital Expenditure | -70.00K | ||
| Net Cash Flow from Investing | -70.00K | ||
| Net Cash Flow from Operations | -24.28M | ||
| Share Based Compensation | 2.47M | ||